BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical- stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT. A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.mon ...

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 337.50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.37 per share when it actually produced earnings of $0.23, delivering a surprise of 162.16%.Over the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84- ...

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on tr ...

Summary of findings: About CDK2 MGDs and MRT-51443 CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy Cyclin-dependent kinase 2 (CDK2) is a key driver of cell cycle progression in cancer, acting in coordination with CDK4 and CDK6 to drive cell proliferation. CDK4/6 inhibitors, in combination with endocrine therapy, are FDA-approved agents for the ...

Monte Rosa Therapeutic (GLUE) Q4 2024 Earnings Call March 20, 2025 01:22 PM ET Company Participants Andrew Funderburk - SVP, Head of Investor Relations & Strategic FinanceMarkus Warmuth - CEOFilip Janku - Chief Medical OfficerSharon Townson - Chief Scientific OfficerRobert Driscoll - SVP - Equity ResearchEllie Merle - ED - Biotech Equity ResearchEva Fortea-Verdejo - Vice President - Biotechnology Conference Call Participants Kelly Shi - SVP & Senior Research Analyst - BiotechnologyEdward Tenthoff - Sr. Rese ...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael ...

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 162.16%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.45 per share when it actually produced a loss of $0.29, delivering a surprise of 35.56%.Over the las ...

Financial Performance - The net loss for the year ended December 31, 2024, was $72.7 million, a decrease of $62.7 million compared to a net loss of $135.4 million in 2023[660]. - The company had an accumulated deficit of $438.6 million as of December 31, 2024[644]. - Net cash provided by operating activities was $41.996 million in 2024, offsetting a net loss of $72.7 million[674]. - Cash used in investing activities was $44.452 million in 2024, primarily due to purchases of marketable securities totaling $230.4 million[676]. - Net cash provided by financing activities amounted to $98.892 million in 2024, mainly from stock offerings[678]. - The existing cash and marketable securities are projected to fund operations for at least the next twelve months[680]. - The company expects to continue incurring losses and will finance operations through equity offerings, debt financings, or collaborations[681]. Revenue and Collaboration Agreements - Collaboration revenue for the year ended December 31, 2024, was $75.6 million, with $34.0 million from Roche and $41.6 million from Novartis[661]. - An upfront payment of $50 million was received from Roche under a collaboration agreement, with potential milestone payments exceeding $2 billion[650]. - An upfront payment of $150 million was received from Novartis, with potential development and sales milestone payments up to $2.1 billion[653]. - The company announced a global exclusive development and commercialization License Agreement with Novartis, receiving an upfront payment of $150 million[671]. - The company entered into a Collaboration and License Agreement with Roche on October 16, 2023, receiving an upfront payment of $50 million and milestone payments of $9 million, with potential contingent payments exceeding $3 billion[700]. - A License Agreement with Novartis was established on October 25, 2024, which includes an upfront payment of $150 million and potential milestone payments up to $2.1 billion, along with tiered royalties on sales outside the United States[701]. Research and Development - Research and development expenses increased to $121.6 million in 2024 from $111.3 million in 2023, reflecting a $10.3 million increase[660]. - Research and development expenses included non-cash stock-based compensation of $10.6 million in 2024, compared to $8.9 million in 2023[663]. - The company expects substantial increases in research and development expenses as it continues to invest in product candidate development and clinical trials[657]. - The company is responsible for ongoing Phase 1 clinical studies under the Novartis Agreement, while Novartis will handle subsequent development and commercialization[701]. General and Administrative Expenses - General and administrative expenses rose to $35.2 million in 2024 from $32.0 million in 2023, driven by increased personnel and professional service costs[665]. Other Financial Metrics - Interest income increased to $10.566 million in 2024 from $9.334 million in 2023, primarily due to higher interest rates on marketable securities[666]. - The company recorded a foreign currency exchange gain of $416, compared to a loss of $930 in 2023, attributed to the strengthening of the U.S. Dollar against the Swiss Franc[667]. - A provision for income taxes of $2.6 million was recorded in 2024, driven by federal and state taxes related to a $50 million upfront payment for the Roche Agreement[668]. Commitments and Agreements - Lease commitments for laboratory and office space in Boston and Basel total $61.6 million, with payments due until 2032 and 2027 respectively[703]. - The company utilizes a percentage of completion method for revenue recognition based on cumulative costs incurred compared to total estimated costs[700]. - The assessment of milestone payments includes evaluating scientific, clinical, regulatory, and commercial risks, with considerable judgment involved[695]. - The company has not experienced significant changes in estimates related to transaction prices or total expected costs as of the latest reporting period[696]. Classification and Reporting - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[705].